Co-administration of a CpG adjuvant (Vaxlmmune™, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice

Human Vaccines

Volumn 5, Issue 2, 2009, Pages 79-84

  Thomas, Lawrence J ^a   Hammond, Russell A ^a   Forsberg, Eric M ^a   Geoghegan Barek, Kathleen M ^a   Karalius, Brad H ^a   Marsh Jr , Henry C ^a   Rittershaus, Charles W ^a  

^a AVANT Immunotherapeutics Inc   (United States)

Author keywords

CETP; Cholesteryl ester transfer protein; CpG; HDL C; LDL

Indexed keywords

AGATOLIMOD; ALUMINUM HYDROXIDE; CETI 1 PEPTIDE VACCINE; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; PADRE CETP PEPTIDE VACCINE; PEPTIDE VACCINE; PROTEIN ANTIBODY; TETANUS TOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; EXPERIMENTAL RABBIT; FEMALE; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; RABBITS; VACCINES, SUBUNIT;

EID: 67549104694     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.2.6521     Document Type: Article

References (26)

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349:1269-76.
2. Rittershaus CW. Vaccines for cholesterol management. World J Surg 2007; 31:690-4.
3. Barter P, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis 1996; 121:1-12.
4. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20:2106-12.
5. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989; 342:448-51.
6. Tall A. Plasma cholesteryl ester transfer protein. J Lipid Res 1993; 341:1255.
7. Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 2003; 169:113-20.
8. McCluskie MJ, Krieg AM. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. In: Pulendran B, Ahmed R, eds. From innate immunity to immunological memory. New York, New York: Springer 2006; 155-78.
9. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-55.
10. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-8.
11. Tall AR. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies. J Intern Med 1995; 237:5-12.
12. Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 2007; 356:1364-6.
13. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002; 105:2159-65.
14. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356:1620-30.
15. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007; 370:1907-14.
16. Gaofu Q, Jun L, Xin Y, Wentao L, Jie W, Xiuyun Z, et al. Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-Cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J Cardiovasc Pharmacol 2005; 45:591-8.
17. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994; 1:751-61.
18. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20:709-60.
19. Lin L, Gerth AJ, Peng SL. CpG DNA redirects class-switching towards "Th1-like" Ig isotype production via TLR9 and MyD88. Eur J Immunol 2004; 34:1483-7.
20. Mullen GE, Giersing BK, Ajose-Popoola O, Davis HL, Kothe C, Zhou H, et al. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 2006; 24:2497-505.
21. Swenson TL, Hesler CB, Brown ML, Quinet E, Trotta PP, Haslanger MF, et al. Mechanism of cholesteryl ester transfer protein inhibition by a neutralizing monoclonal antibody and mapping of the monoclonal antibody epitope. J Biol Chem 1989; 264:14318-26.
22. Hesler CB, Brown ML, Feuer DS, Marcel YL, Milne RW, Tall AR. Structure-function analysis of plasma cholesteryl ester transfer protein by protease digestion and expression of cDNA fragments in Escherichia coli. J Biological Chemistry 1989; 1989:11317-25.
23. Yen FT, Deckelbaum RJ, Mann CJ, Marcel YL, Milne RW, Tall AR. Inhibition of cholesteryl ester transfer protein activity by monoclonal antibody. Effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma. J Clin Invest 1989; 83:2018-24.
24. Whitlock ME, Swenson TL, Ramakrishnan R, Leonard MT, Marcel YL, Milne RW, et al. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. J Clin Invest 1989; 84:129-37.
25. Thomas LJ, Picard MD, Miller DP, Adari H, Beattie DT, Emmett CD, et al. Modifications of the cholesterol-fed rabbit model of atherosclerosis using diets with different levels of cholesterol-supplementation. Preclinica 2003; 1:60-9.
26. Panina-Borgignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989; 19:2237-42.